您的购物车当前为空
别名 迈泽妥单抗, TAK-079, TAK079
Mezagitamab (TAK-079) 是一种全人源抗 CD38 的IgG1λ 单克隆抗体,对表达CD38的细胞(包括浆母细胞、浆细胞、自然杀伤细胞)具有高亲和力,通过抗体和补体依赖性细胞毒性耗尽表达 CD38 的肿瘤细胞。Mezagitamab 可用于研究复发/难治性多发性骨髓瘤 (RRMM) 和原发性血小板减少性紫癜 (ITP)。

为众多的药物研发团队赋能,
让新药发现更简单!
Mezagitamab (TAK-079) 是一种全人源抗 CD38 的IgG1λ 单克隆抗体,对表达CD38的细胞(包括浆母细胞、浆细胞、自然杀伤细胞)具有高亲和力,通过抗体和补体依赖性细胞毒性耗尽表达 CD38 的肿瘤细胞。Mezagitamab 可用于研究复发/难治性多发性骨髓瘤 (RRMM) 和原发性血小板减少性紫癜 (ITP)。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,480 | In Stock | |
| 5 mg | ¥ 5,860 | In Stock | |
| 10 mg | ¥ 7,890 | In Stock | |
| 25 mg | ¥ 11,700 | In Stock | |
| 50 mg | ¥ 15,800 | In Stock |
Mezagitamab 相关产品
| 产品描述 | Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent/refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP). |
| 别名 | 迈泽妥单抗, TAK-079, TAK079 |
| CAS No. | 2227490-52-8 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容